Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
Total Valuation
Cytek Biosciences has a market cap or net worth of $450.90M. The enterprise value is $588.41M.
Market Cap$450.90M
Enterprise Value$588.41M
Share Statistics
Cytek Biosciences has 128.10M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding128.10M
Owened by Insiders9.16%
Owened by Instutions13.95%
Financial Efficiency
Cytek Biosciences’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -5.02%.
Return on Equity (ROE)-1.52%
Return on Assets (ROA)-1.21%
Return on Invested Capital (ROIC)-5.02%
Return on Capital Employed (ROCE)-4.75%
Revenue Per Employee$272,575.617
Profits Per Employee-$9,288.58
Employee Count648
Asset Turnover0.40
Inventory Turnover2.04
Valuation Ratios
The current PE Ratio of Cytek Biosciences is -141.23. Cytek Biosciences’s PEG ratio is 1.41.
PE Ratio-141.23
PS Ratio4.24
PB Ratio2.15
Price to Fair Value2.15
Price to FCF38.90
Price to Operating Cash Flow33.50
PEG Ratio1.41
Income Statement
In the last 12 months, Cytek Biosciences had revenue of $176.63M and earned -$6.02M in profits. Earnings per share was -$0.05.
Revenue$176.63M
Gross Profit$111.11M
Operating Income-$19.12M
Pretax Income-$5.70M
Net Income-$6.02M
EBITDA-10.03M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was $25.38M and capital expenditures -$3.53M, giving a free cash flow of $21.84M billion.
Operating Cash Flow$25.38M
Free Cash Flow$21.84M
Free Cash Flow per Share$0.17
Dividends & Yields
Cytek Biosciences pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield2.57%
Earnings Yield-0.71%
Stock Price Statistics
Beta1.63
52-Week Price Change-39.87%
50-Day Moving Average4.53
200-Day Moving Average5.52
Relative Strength Index (RSI)30.28
Average Volume (3m)970.68K
Important Dates
Cytek Biosciences upcoming earnings date is May 7, 2025, After Close.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Cytek Biosciences as a current ratio of 5.86, with Debt / Equity ratio of 0.02
Current Ratio5.86
Quick Ratio5.21
Debt to Market Cap<0.01
Net Debt to EBITDA4.44
Interest Coverage Ratio-3.92
Taxes
In the past 12 months, Cytek Biosciences has paid $320.00K in taxes.
Income Tax$320.00K
Effective Tax Rate-5.61%
Enterprise Valuation
Cytek Biosciences EV to EBITDA ratio is -36.99, with an EV/FCF ratio of 34.73.
EV to Sales3.79
EV to EBITDA-36.99
EV to Free Cash Flow34.73
EV to Operating Cash Flow29.91
Balance Sheet
Cytek Biosciences has $277.86M in cash and marketable securities with $7.55M in debt, giving a net cash position of -$270.31M billion.
Cash & Marketable Securities$277.86M
Total Debt$7.55M
Net Cash-$270.31M
Net Cash Per Share-$2.11
Tangible Book Value Per Share$2.74
Margins
Gross margin is 55.43%, with operating margin of -10.24%, and net profit margin of -3.00%.
Gross Margin55.43%
Operating Margin-10.24%
Pretax Margin-2.84%
Net Profit Margin-3.00%
EBITDA Margin-10.24%
EBIT Margin-10.24%
Analyst Forecast
The average price target for Cytek Biosciences is $7.13, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$7.13
Price Target Upside102.56%
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast3.85%
EPS Growth Forecast49.09%